<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1459">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142163</url>
  </required_header>
  <id_info>
    <org_study_id>RGCI/GDFT</org_study_id>
    <nct_id>NCT05142163</nct_id>
  </id_info>
  <brief_title>Stroke Volume Variation and Plethysmography Variability Index as Goal Directed Fluid Therapy in Major Oncosurgeries</brief_title>
  <acronym>SVV PVI GDFT</acronym>
  <official_title>Stroke Volume Variation and Plethysmography Variability Index as Goal Directed Fluid Therapy in Major Oncosurgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajiv Gandhi Cancer Institute &amp; Research Center, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajiv Gandhi Cancer Institute &amp; Research Center, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients were allotted to two Groups , SVV Guided Fluid Therapy Group received intraoperative&#xD;
      fluids to maintain SVV &lt;11 , and PVI Guided Group received intraoperative Fluids to maintain&#xD;
      PVI&lt;11&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preinduction Epidural catheter will be placed and Standard General Anaesthesia with Volume&#xD;
      Controlled Ventilation (Tidal Volume 8ml/Kilogram ) and Positive End Expiratory Pressure 5&#xD;
      centimeters of water for all patients. Postinduction Radial artery cannulation and Ultrasound&#xD;
      guided Internal Jugular cannulation will be performed for all patients .Maintenance Fluid&#xD;
      crystalloids 2ml/kg will be given to both the Groups. In Stroke Volume Variation SVV Group&#xD;
      Flotrac Transducer (MHD8 model Edwards Lifesciences LLC, Irvine,CA 92614,USA) will be&#xD;
      attached to radial artery cannula to obtain SVV values and for values &lt; 11 colloid bolus&#xD;
      200ml will be given over 10 minutes and postbolus values noted. In Plethysmography&#xD;
      Variability Index PVI Group pulse Oximeter will be placed on index finger and covered to&#xD;
      avoid ambient light will be attached to Masimo Radical 97 Monitor to measure continuous&#xD;
      Perfusion Index and Plethysmography Variability Index for values &lt;11 colloid bolus 200ml will&#xD;
      be given over 10 minutes and change in PVI value noted. Intraoperative heart rate , Mean&#xD;
      arterial Pressure , Oxygen Saturation, End tidal carbon dioxide, Central venous pressure ,&#xD;
      Urine output will be measured in all patients.With optimal fluids if Mean Arterial Pressure&#xD;
      is below 70 mmHg than titrating dosage Norepinephrine infusion will be commenced.At the end&#xD;
      of surgery reversal agents will be administered and trachea extubated , note will be made of&#xD;
      any patient requiring postoperative ventilator support.Arterial blood gas analysis will be&#xD;
      performed at beginning and end of surgery and at postoperative 24 and 48 hours to measure&#xD;
      serum lactate levels . Patient will be monitored in Postanaesthesia Care Unit for any Cardiac&#xD;
      , Respiratory event , Serum Creatinine levels will be measures at 24 and 48 hours ,&#xD;
      Appearance of bowel sounds will be noted , Length of ICU stay will be recorded for all&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2021</start_date>
  <completion_date type="Anticipated">February 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were allotted to either SVV Guided or PVI Guided Intraoperative Fluid Therapy</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patient were masked about belonging to SVV Guided or PVI Guided Group to receive Intraoperative Fluid Therapy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To compare Total intraoperative Fluid requirement in millilitres and Fluid Responsiveness in SVV and PVI Group.</measure>
    <time_frame>upto 8 hours</time_frame>
    <description>Patients in SVV Group will receive Crystalloids and colloid bolus 200ml to maintain SVV &lt;11 .Patients in PVI Group will receive Crystalloids and colloid bolus to maintain PVI&lt;11, Postbolus response to SVV and PVI values will be noted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Measure Serum Lactate levels mmol/L in SVV and PVI Group.</measure>
    <time_frame>upto 72 hours postoperative</time_frame>
    <description>Intraoperative at beginning and end of surgery and upto 72 hours serum Lactate levels will&#xD;
be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Cardiac complication</measure>
    <time_frame>upto72 hours</time_frame>
    <description>Requirement of Inotrope Nonadrenaline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Respiratory complication</measure>
    <time_frame>upto 72 hours</time_frame>
    <description>Ventilator support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Renal complication</measure>
    <time_frame>upto72 hours</time_frame>
    <description>Increase serum creatinine values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>upto72 hours</time_frame>
    <description>Duration in hours stay in PACU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Goal Directed Fluid Therapy</condition>
  <arm_group>
    <arm_group_label>Stroke Volume Variation Guided Fluid Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive maintenance Fluids as crystalloids intraoperative to maintain SVV &lt;11%, for values &gt;11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plethysmography Variability Index Guided Fluid Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive maintenance Fluids as crystalloids intraoperative to maintain PVI &lt;10%, for values &gt;10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraoperative SVV Guided Fluid Therapy</intervention_name>
    <description>Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV &lt;11%, for values &gt;11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.</description>
    <arm_group_label>Stroke Volume Variation Guided Fluid Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraoperative PVI Guided Fluid Therapy</intervention_name>
    <description>Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI &lt;10%, for values &gt;10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.</description>
    <arm_group_label>Plethysmography Variability Index Guided Fluid Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients undergoing Open major Oncosurgeries under General Anaesthesia&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patient Refusal&#xD;
&#xD;
        Left ventricular Ejection Fraction &lt;40%&#xD;
&#xD;
        Cardiac arrythmias&#xD;
&#xD;
        Severe valvular heart disease&#xD;
&#xD;
        Peripheral Vascular Disease&#xD;
&#xD;
        Laparoscopic surgeries&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Kulkarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anita Kulkarni, MD</last_name>
    <phone>09892064785</phone>
    <email>anitackulkarni@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohinderjeet Kaur, MBBS</last_name>
    <phone>09592079303</phone>
    <email>mohi.chd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute and Research Centre</name>
      <address>
        <city>Delhi</city>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kulkarni, MD</last_name>
      <phone>+91 9891064785</phone>
      <email>anitackulkarni@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anita Kulkarni, M.D.</last_name>
      <phone>+919891064785</phone>
      <email>anitackulkarni@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rajiv Gandhi Cancer Institute &amp; Research Center, India</investigator_affiliation>
    <investigator_full_name>Dr Anita Kulkarni</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Goal directed Fluid Therapy</keyword>
  <keyword>Stroke Volume Variation</keyword>
  <keyword>Plethysmography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

